Spots Global Cancer Trial Database for Adjuvant Tebentafusp in High Risk Ocular Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Adjuvant Tebentafusp in High Risk Ocular Melanoma
Official Title: Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*0201 Positive Patients With High-risk Non-metastatic Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
Study ID: NCT06246149
Conditions
Interventions
Study Description
Brief Summary: At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Paul Nathan
Affiliation: Mount Vernon Cancer Centre, Northwood, UK
Role: PRINCIPAL_INVESTIGATOR
Name: Richard D. Carvajal
Affiliation: Northwell Health Cancer Institute, NY, USA
Role: PRINCIPAL_INVESTIGATOR
Name: Serge Leyvraz
Affiliation: Charité Hospital, Berlin, Germany
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
